Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

4 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Esophagogastroduodenoscopy Week 38 Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Week 38

- 15/7/17 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Esophagogastroduodenoscopy Week 16 Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Week 16

- 12/7/17 - 1 Formulário, 1 Grupo de itens, 3 Elementos de dados, 1 Idioma
Grupo de itens: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Week 16.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Esophagogastroduodenoscopy Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Day 1 Pre-Infusion

- 11/6/17 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

HES Related Medical Conditions Screening Visit Mepolizumab HES NCT00086658 - HES Related Medical Conditions Screening Visit

- 4/6/17 - 1 Formulário, 8 Grupos de itens, 34 Elementos de dados, 1 Idioma
Grupos de itens: Cardiac disorders, NERVOUS SYSTEM DISORDERS, Skin diseases, GASTROINTESTINAL DISORDERS, MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, EYE DISORDERS, RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, medical history Hypereosinophilic Syndrome
Study part: HES Related Medical Conditions Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial